Wall Street brokerages expect AC Immune SA (NASDAQ:ACIU) to announce sales of $4.18 million for the current fiscal quarter, Zacks Investment Research reports. Two analysts have provided estimates for AC Immune SA’s earnings, with the highest sales estimate coming in at $7.00 million and the lowest estimate coming in at $1.35 million. The firm is expected to report its next earnings report on Wednesday, November 8th.

According to Zacks, analysts expect that AC Immune SA will report full-year sales of $4.18 million for the current fiscal year, with estimates ranging from $16.80 million to $22.87 million. For the next fiscal year, analysts forecast that the firm will report sales of $25.54 million per share, with estimates ranging from $25.47 million to $25.60 million. Zacks’ sales calculations are a mean average based on a survey of sell-side analysts that follow AC Immune SA.

A number of equities analysts recently issued reports on the company. Zacks Investment Research upgraded AC Immune SA from a “sell” rating to a “hold” rating in a report on Monday, October 16th. Credit Suisse Group set a $18.00 price target on AC Immune SA and gave the company a “buy” rating in a research report on Wednesday, July 19th.

COPYRIGHT VIOLATION NOTICE: “$4.18 Million in Sales Expected for AC Immune SA (ACIU) This Quarter” was originally reported by American Banking News and is the property of of American Banking News. If you are viewing this story on another site, it was stolen and republished in violation of international copyright and trademark law. The legal version of this story can be viewed at https://www.americanbankingnews.com/2017/11/03/4-18-million-in-sales-expected-for-ac-immune-sa-aciu-this-quarter.html.

An institutional investor recently bought a new position in AC Immune SA stock. Goldman Sachs Group Inc. bought a new stake in shares of AC Immune SA (NASDAQ:ACIU) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 14,475 shares of the company’s stock, valued at approximately $127,000. 18.06% of the stock is owned by hedge funds and other institutional investors.

About AC Immune SA

AC Immune Ltd is a Switzerland-based company engaged in the medical biotechnology sector. It develops treatments for Alzheimer’s and other neurodegenerative diseases, such as Down syndrome, glaucoma and Parkinson’s, and focuses on producing therapeutic and diagnostic product candidates, using SupraAntigen and Morphomer technology platforms.

Get a free copy of the Zacks research report on AC Immune SA (ACIU)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for AC Immune SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AC Immune SA and related companies with MarketBeat.com's FREE daily email newsletter.